Member Info for HotblackDesiato

Whilst the FDA no longer needs animal tests before human drug trials, the last thing we need is another MHRA-type fiasco so it's probably better to have 2-species data on hand should any state authority require it.

https://www.science.org/content/article/fda-no-longer-needs-require-animal-tests-human-drug-trials

https://www.understandinganimalresearch.org.uk/news/do-we-need-to-test-all-new-drugs-in-two-species

Regards.

Hi NAV - meh, if the sp remains around here for a while then just take advantage of it if you can. The BoD were pretty clear that there is no bad news waiting to trip us up; excellent SAD/MAD results, interested parties steering us towards further tox to prep for P2a, 737 milestones on the way etc. Yes, it's a waiting game for now but at least we know we're waiting for good news rather than waiting on unknowns.

The market doesn't like uncertainty but the presentation gave a strong message that all is well and we have the cash to be firing on all cylinders.

Evening Meg - there had been some speculation that the govt might try to put a £100k cap on ISAs, see link below. I think a few of us here are above that figure even before SAR's sp gets motoring again.

https://www.thisismoney.co.uk/money/investing/article-13489035/Could-future-government-cap-Isa-savings.html

Other info worth a look -

https://www.finder.com/uk/share-trading/share-trading-research/stocks-and-shares-isa-statistics

https://www.gov.uk/government/statistics/annual-savings-statistics-2024/commentary-for-annual-savings-statistics-september-2024

Regards.

I get what you're saying, Oddmoney, but if all the tax evaders decided to be honest then the Treasury would have about £40bn more each year to play with...or spaff on vanity projects.

For clarity, tax avoidance is legal (putting money into an ISA is a form of tax avoidance) whereas tax evasion is illegal and costs every person in the UK.

Https://sareum.com/wp-content/uploads/2024/10/Sareum-FY-Results-Oct-2024.pdf

Yep, BB. The first clue was when they reduced the £6k ceiling to just £3k. That was just the start. With no increase in what you can put into an ISA it's clear the govt is almost anti-investment. Time to look at off-shore trust funds!

Hi Warthog - it might serve you well to listen to the presentation before passing comment.

Hi Bobbler - I asked a similar question at a previous meeting and TM said whilst not impossible, a licencee would generally want a compound for all possible indications. I guess if you're paying big bucks then you don't want to reduce your options which is understandable.

Glad they answered all my questions first except why Halifax customers couldn't take part in the Spring raise.

So P1b deemed immaterial by potential partners therefore further tox required to match the length of proposed P2a studies. Peer reviewed 1801 data due before the end of the year (2mths tops) plus word on who has 737 as it'd be odd to own shares in a company but not know who that is.

Form an orderly queue and just sit tight on your shares until the cat's out the bag.

Onwards!

Hi BenH/Warthog - would the backers involved in the recent £3.3m of funding have done so if they thought we'd fallen so far behind in terms of development that we've missed any window of opportunity? That said, I hope the BoD can now accelerate 1802 out of the interminable translation studies and I believe everything is still to play for since 1801 & 2 aren't one-trick ponies and should be able to target multiple indications.

Fair point, Krone.

Just thinking aloud. What if Krone's find, Treeline Bioscience, wanted to buy us out? They are currently hiding their pipeline from view and so I presume they'd want some anonymity if they put forward a T/O offer.

One question is, would knowing who an offer was from feature in your decision to accept or reject it or would it simply come down to the size/terms of the offer? My point being, if an offer came from a major pharma, we might know roughly how deep their pockets are so that could give some confidence to reject an offer on the assumption they could afford to up their bid. Whereas we wouldn't have that luxury if an unknown pharma made the offer - is that the best they can do and it's a straight take it or leave it, one-time offer?

Another question is, could Treeline (or similar) make a binding offer under an NDA that says if we run and prove 1801 is safe under extended tox studies (no chance of a black box warning), then they'll offer £x? However if 1801 throws up tox issues the offer is null and void.

Even T&J's fiercest critics would probably agree they're not the type to blab about potential deals etc. but that doesn't mean people working for lawyers etc. have the same level of discretion. Allegedly. Large trades ahead of forward look statement, cough cough, large trades, cough cough.

Evening SOG - I seem to remember Thoth suggesting that once we begin seeing significantly larger trades than the usual £500 here, £2000 there, then the game's afoot as the bigger players start moving in.

Too much of a coincidence that all those really chunky trades over the last few days have been reported as 'unknown' rather than clear buys or sells. Sales of smoke and mirrors to MMs have increased but to whose benefit?

Hi Rebster - re your query on Boehringer Ingelheim. They're privately owned so I think that rules them out of the 737 equation as I'm not sure how forthcoming milestone shares would be valued if they're not publicly traded. Plus they are loaded so I wouldn't have expected to see a bit in the license agreement relating to being able to access funds to develop 737.

As far as I can see, the current 737 front runners are either Sierra since there are so many similarities between the original deal and the latest one and Treeline Biosciences unearthed by Krone. They claim to be building a pipeline and will announce it to the public at some point plus they recently raised $400m+ so they certainly have the cash to put 737 through P3 trials.

Surfie - and if people find me sanctimonious then please filter me, I won't be offended in any way.

Hi Blue - I'd like to clarify a few things. I try to be as helpful as I can by posting links and so on in the hope that it expands the group knowledge here. I've seen the sp highs and the lows just like everyone else. I see no point in posting my own complaints about where the current sp is - how would that help matters? I am not privy to any of the discussions/events at SAR HQ so I just have to accept the situation with the same info as you or anyone else has and it is my choice to wait for the big pay-off, if or when it comes. Failure in business is always an option.

There are some posters here who add next to nothing in terms of either helping others or sharing research - fine, no problem, no one is obliged to work on behalf of other shareholders. What I find annoying is when some do nothing but complain. Post after post of misery. Why an individual puts themselves through that is beyond me. I had a large sum invested in another share that was failing and rather than post about how unhappy I was, I sold and moved on.

If I come across as sanctimonious then it certainly isn't intended but do you not think the serial complainers should reconsider their options and just bail out if they are constantly unhappy?

I'm now off to dust behind the skirting boards of my ivory tower. I always thought it more 'oat mealy' rather than ivory, but there you go.

Regards.

I think much of the negativity here is akin to getting a table in a crowded restaurant with full prior knowledge that there is just one chef and one waiter and then expecting to be served when it suits you. If you invest in a 2-man operation (ok, 3 now that SP has exec powers), which is already competing with and trying to beat global players, there must be something that keeps you from walking out.

If the menu keeps changing you can either remain because you feel it'll still be worth the wait or you can pick another place to eat. Or maybe some never intended to eat in the first place and are just here for the ambience.

Just for info - https://www.marketscreener.com/quote/stock/SAREUM-HOLDINGS-PLC-118683111/company-shareholders/

Might be interesting to compare the numbers again once the new shares are added later in the week.

Hi SOG - the link below is dated 18th Oct 2024 and lists Sierra Oncology as using 737 for Fanconi Anemia (which I thought was an Italian dessert). Not sure if the article is just relying on data lifted from the results of Sierra's two 737 trials from a few years ago or if the report has access to something a bit more current; keep in mind that fully self-funded trials do not have to be registered on the US Govt. trial website.

https://www.abnewswire.com/pressreleases/fanconi-anemia-pipeline-forecast-2024-fda-approvals-therapies-and-leading-companies-foresee-pharma-rocket-pharma-john-diaz-novartis-sierra-oncology_717380.html

Emerging Fanconi Anemia Drugs Under Different Phases of Clinical Development Include:

FP-045: Foresee Pharmaceuticals

RP-L102: Rocket Pharmaceuticals

pembrolizumab: John Diaz

Abatacept: Emory University

ICL670: Novartis

SRA737: Sierra Oncology

Regards.

Hi SOG - don't know if you've tried the Chinese Clinical Trial register (link below). Whilst it has an English language site, once you search for SRA737 as the intervention you are taken to a security page where you have to swipe/slide a cursor to the right. Once you do that you seem to get blocked - probably as I'm not in China.

Anyone here with Chinese connections that can take a look?

https://www.chictr.org.cn/searchprojEN.html